Asociación de esquizofrenia y sus dimensiones clínicas con el gen NOS1AP en población colombiana*

American Psychiatric Association, 2000 Organización Mundial de la Salud, 1992 World Health Organization (WHO), 2001 Sullivan, 2003, Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies, Arch Gen Psychiatry, 60, 1187, 10.1001/archpsyc.60.12.1187 Gejman, 2011, Genetics of schizophrenia: new findings and challenges, Annu Rev Genomics Hum Genet, 12, 121, 10.1146/annurev-genom-082410-101459 Nothen, 2010, New findings in the genetics of major psychoses, Dialogues Clin Neurosci, 12, 85, 10.31887/DCNS.2010.12.1/mnoethen Brzustowicz, 2004, Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22, Am J Hum Genet, 74, 1057, 10.1086/420774 Miranda, 2006, Putative association of the carboxy-terminal PDZ ligand of neuronal nitric oxide synthase gene (CAPON) with schizophrenia in a Colombian population, Schizophr Res, 82, 283, 10.1016/j.schres.2005.10.018 Rosa, 2002, 1q21-q22 locus is associated with susceptibility to the reality-distortion syndrome of schizophrenia spectrum disorders, Am J Med Genet, 114, 516, 10.1002/ajmg.10526 Lewis, 2003, Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia, Am J Hum Genet, 73, 34, 10.1086/376549 Gurling, 2001, Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23, Am J Hum Genet, 68, 661, 10.1086/318788 Brzustowicz, 2002, Fine mapping of the schizophrenia susceptibility locus on chromosome 1q22, Hum Hered, 54, 199, 10.1159/000070665 Brzustowicz, 2000, Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22, Science, 288, 678, 10.1126/science.288.5466.678 Brzustowicz, 2008, NOS1AP in schizophrenia, Curr Psychiatry Rep, 10, 158, 10.1007/s11920-008-0027-0 Ledo, 2004, Nitric oxide in brain: diffusion, targets and concentration dynamics in hippocampal subregions, Mol Asp Med, 25, 75, 10.1016/j.mam.2004.02.010 Che, 2000, Changes in mRNA for post-synaptic density-95PSD-95/and carboxy-terminal PDZ ligand of neuronal nitric oxide synthase followingfacial nerve transection, Mol Brain Res, 76, 325, 10.1016/S0169-328X(00)00013-9 Jaffrey, 1998, CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95, Neuron, 20, 115, 10.1016/S0896-6273(00)80439-0 Bennett, 2009, Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression, Aust N Z J Psychiatry, 43, 711, 10.1080/00048670903001943 Graham, 2002, Dexras1/AGS-1inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases, J Biol Chem, 277, 10876, 10.1074/jbc.M110397200 Chen, 2004, Positive association between synapsin II and schizophrenia, Biol Psychiatry, 56, 177, 10.1016/j.biopsych.2004.05.010 Carrel, 2009, NOS1AP regulates dendrite patterning of hippocampal neurons through a carboxypeptidase E-mediated pathway, J Neurosci, 29, 8248, 10.1523/JNEUROSCI.5287-08.2009 Xu, 2005, Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder, PLoS Med, 2, e263, 10.1371/journal.pmed.0020263 Zheng, 2005, Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population, Biochem Biophys Res Commun, 328, 809, 10.1016/j.bbrc.2005.01.037 Fang, 2008, Family-based association studies of CAPON and schizophrenia in the Chinese Han population, Prog Neuropsychopharmacol Biol Psychiatry, 32, 1210, 10.1016/j.pnpbp.2008.03.007 Puri, 2006, Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample, Biol Psychiatry, 59, 195, 10.1016/j.biopsych.2005.08.015 Puri, 2008, Confirmation of the genetic association between the U2AF homology motif (UHM) kinase 1 (UHMK1) gene and schizophrenia on chromosome 1q23.3, Eur J Hum Genet, 16, 1275, 10.1038/ejhg.2008.76 Kremeyer, 2009, Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate, Hum Hered, 67, 163, 10.1159/000181154 Tsuang, 2000, Toward reformulating the diagnosis of schizophrenia, Am J Psychiatry, 157, 1041, 10.1176/appi.ajp.157.7.1041 Fanous, 2005, Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework, Mol Psychiatry, 10, 6, 10.1038/sj.mp.4001571 Derosse, 2008, The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia, Schizophr Bull, 34, 1047, 10.1093/schbul/sbn076 Peralta, 2001, How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment, Schizophr Res, 49, 269, 10.1016/S0920-9964(00)00071-2 Tandon, 2009, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr Res, 110, 1, 10.1016/j.schres.2009.03.005 Andreasen, 1984 Andreasen, 1989, The Scale for the Assessment of Negative Symtoms (SANS): a conceptual and theorical foundations, Br J Psychiatry, 49, 10.1192/S0007125000291496 Peralta, 1999, Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders, Schizophr Res, 38, 13, 10.1016/S0920-9964(99)00003-1 Nurnberger, 1994, Diagnostic Interview for Genetic Studies: rationales, unique features and training, Arch Gen Psychiatry, 51, 849, 10.1001/archpsyc.1994.03950110009002 Palacio, 2004, Validación de la entrevista diagnóstica para estudios genéticos (DIGS) en Colombia, Biomédica, 24, 56, 10.7705/biomedica.v24i1.1249 García, 2003, Inferencias fenomenológicas y nosológicas en la esquizofrenia a partir de la validación de las escalas de síntomas positivos (SAPS) y de síntomas negativos (SANS) en Colombia, Rev Neuro-Psiquiatría, 66, 195, 10.20453/rnp.v66i3.1545 Kawasaki, 1990, Sample preparation from blood, cells and other fluids, 146 Zhang, 2003, On a semi-parametric test to detect associations between quantitative traits and candidate genes using unrelated individuals, Gen Epidemiol, 24, 44, 10.1002/gepi.10196 Woods, 2003, Chlorpromazine equivalent doses for the newer atypical antipsychotics, J Clin Psychiatry, 64, 663, 10.4088/JCP.v64n0607 Wratten, 2009, Identification of a schizophrenia-associated functional noncoding variant in NOS1AP, Am J Psychiatry, 166, 434, 10.1176/appi.ajp.2008.08081266 Puri, 2007, Fine mapping by genetic association implicates the chromosome 1q23.3 gene UHMK1, encoding a serine/threonine protein kinase, as a novel schizophrenia susceptibility gene, Biol Psychiatry, 61, 873, 10.1016/j.biopsych.2006.06.014 Talkowski, 2006, Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples, Biol Psychiatry, 60, 152, 10.1016/j.biopsych.2006.02.015 Goghari, 2010, The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question, Neurosci Biobehav Rev, 34, 468, 10.1016/j.neubiorev.2009.09.004 Toomey, 1997, Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients, Am J Psychiatry, 154, 371, 10.1176/ajp.154.3.371 Arajarvi, 2006, Affective flattening and alogia associate with the familial form of schizophrenia, Psychiatry Res, 141, 161, 10.1016/j.psychres.2005.08.008 Jablensky, 2006, Subtyping schizophrenia: implications for genetic research, Mol Psychiatry, 11, 815, 10.1038/sj.mp.4001857